Ernexa Therapeutics Inc. (NASDAQ:ERNA) Sees Large Decline in Short Interest

Posted by George Bondi on Jul 29th, 2026

Ernexa Therapeutics Inc. (NASDAQ:ERNA – Get Free Report) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totaling 14,740 shares, a decline of 49.8% from the June 30th total of 29,381 shares. Based on an average trading volume of 2,478,882 shares, the short-interest ratio is currently 0.0 days. Approximately 1.3% of the company’s stock are short sold.

Hedge Funds Weigh In On Ernexa Therapeutics

An institutional investor recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new position in Ernexa Therapeutics Inc. (NASDAQ:ERNA – Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 70.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Zacks Research upgraded shares of Ernexa Therapeutics to a “hold” rating in a report on Monday, May 11th. Wall Street Zen upgraded Ernexa Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Brookline Capital Markets assumed coverage on Ernexa Therapeutics in a research report on Thursday, May 7th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $30.00.

Read Our Latest Stock Report on Ernexa Therapeutics

Ernexa Therapeutics Price Performance

ERNA stock traded down $0.14 during trading on Wednesday, hitting $3.47. 21,231 shares of the stock traded hands, compared to its average volume of 937,439. The stock has a market cap of $4.06 million, a price-to-earnings ratio of -0.13 and a beta of 2.50. Ernexa Therapeutics has a 1 year low of $3.18 and a 1 year high of $71.50. The firm’s 50 day moving average is $7.11 and its two-hundred day moving average is $10.27.

Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) last issued its earnings results on Monday, May 11th. The company reported ($6.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by ($5.00). As a group, analysts anticipate that Ernexa Therapeutics will post -18.02 EPS for the current fiscal year.

About Ernexa Therapeutics

(Get Free Report)

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.